Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation

Table 1 Comparison of general information of the patients between the two groups

Group	n	Gender(n)		Age (yr)			Colorectal cancer
		Male	Female	Max	Min	mean ± SD	Colon cancer	Rectal caner
Experimental	35	21	14	67	40	52.24 ± 13.20	28	7
Control	33	22	11	68	42	55.63 ± 12.39	25	8

Table 2 Hand-foot skin reactions (National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0)

Grade	Item description
0	No clinical manifestations
1	Have red or discolored skin or painless dermatitis
2	Show changes in skin (such as peeling, bleeding, and swollen) or have blisters or sores, without any dysfunction
3	Show changes in skin due to dysfunctions caused by ulcerative dermatitis or pain

Table 3 Gastrointestinal reactions (National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0)

Grade	Item description
0	No clinical manifestations
1	Lack of appetite, without any change in eating habits
2	Less food intake, no significant weight loss or malnutrition, have signs of intravenous fluid replacement for < 24 h
3	Less energy and water intake, have signs of intravenous fluid rehydration, tube feeding and parenteral nutrition ≥ 24 h

Table 4 Comparisons of scores of traditional Chinese medicine symptoms between the two groups (mean ± SD points)

Group	n	Poor appetite	Abdominal distention	Loose stool	Fatigue	Emaciation
Experimental	35	1.11 ± 0.760a	1.40 ± 0.728a	1.37 ± 0.209a	1.37 ± 0.501a	1.54 ± 0.625a
Control	33	2.75 ± 0.741	2.21 ± 0.753	2.64 ± 0.521	2.24 ± 1.122	2.15 ± 0.917

^aP < 0.05 vs control group.

Table 5 Comparison of Karnofsky performance scale scores between the two groups (mean ± SD points)

Group	n	Before the treatments	After the treatments
Experimental	35	79.17 ± 4.125	88.51 ± 6.773a,d
Control	33	78.75 ± 3.475	81.44 ± 4.539a

^aP < 0.05 vs before treatment.

^dP < 0.05 vs control group.

Table 6 Comparison of serum levels of T-cell subsets between groups before and after the treatments (mean ± SD)

Group	n	Time	CD3+ (%)	CD4+ (%)	CD4+/CD8 (%)	CD8+ (%)
Experimental	35	Before treatment	41.52 ± 5.21	32.07 ± 3.31	0.51 ± 0.15	52.25 ± 5.37
		After treatment	62.3 ± 5.53a,d	43.4 ± 4.99a,d	1.02 ± 0.29a,d	40.52 ± 4.58a,d
Control	33	Before treatment	42.52 ± 4.58	31.15 ± 3.25	0.55 ± 0.13	52.12 ± 6.59
		After treatment	53.25 ± .6.62a	37.72 ± 4.56a	0.77 ± 0.15a	48.46 ± 5.58a

^aP < 0.05 vs before treatment.

^dP < 0.05 vs control group.

Table 7 Comparison of grades of nausea between the two groups

Group	n	Grade
		0	1	2	3
Experimental	35	12	15	7	1
Control	33	4	7	16	6

Table 8 Grades of hand-foot skin reactions between the two groups

Group	n	Grade
		0	1	2	3
Experimental	35	10	13	11	1
Control	33	3	8	19	3

Table 9 Adverse effects between the two groups, n (%)

Group	n	Myelosuppression	Liver dysfunction	Renal dysfunction	Coagulation disorder	ECG abnormality
Experimental	35	8 (22.8)	7 (20.0)	1 (2.8)	3 (8.5)	3 (8.5)
Control	33	6 (18.1)	5 (15.1)	2 (6.0)	3 (9.1)	2 (6.1)

ECG: Electrocardiogram.